Physician profile
Vikrum Malhotra
NPI 1770745275
$44,490.90
in general payments reported to CMS, 2019-2025
25 companies · $25.88 in 2025
The $25.88 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $3,648 · 2021: $3,944 · 2022: $670 · 2023: $1,500 · 2024: $162 · 2025: $25.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Food and Beverage: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Food and Beverage | $188.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $30,454.23 | 2019-2025 | Varithena Administration Pack |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9,930.86 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $1,359.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $471.14 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $365.08 | 2019-2022 | |
| Abbott Laboratories | $354.85 | 2019-2022 | |
| Amgen INC. | $286.50 | 2019-2022 | |
| Medtronic, INC. | $285.20 | 2021-2024 | Aurora Ev-Icd Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $196.74 | 2019-2021 | |
| Dexcom, INC. | $154.74 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $147.54 | 2021-2022 | |
| Medtronic Vascular, INC. | $136.44 | 2019-2020 | |
| Pfizer INC. | $56.61 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.75 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $28.64 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $28.20 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.39 | 2019 | |
| Althera Pharmaceuticals LLC | $25.93 | 2021 | |
| Mannkind Corporation | $25.43 | 2022 | |
| Edwards Lifesciences Corporation | $22.45 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.31 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.62 | 2019 | |
| Vifor Pharma, INC. | $14.26 | 2021 | |
| Akcea Therapeutics, INC. | $14.11 | 2019 | |
| Amarin Pharma, INC. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikrum Malhotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.